BioSpace News Archive

ORIC Pharmaceuticals announced that Jacob Chacko, MD, Chief Executive Officer, will host one-on-one investor meetings on Wednesday, February 27 at the 8th Annual SVB Leerink Global Healthcare Conference, held Wednesday, February 27 through Friday, March 1, 2019 at the Lotte New York Palace in New York City.

Vapotherm, Inc. announced that it will release financial results for the fourth quarter and fiscal year 2018 after the close of trading on Tuesday, March 12, 2019.

Phase 1/2 combination clinical trial evaluating Torque’s Deep IL-15 Primed T Cells (TRQ-1501) and KEYTRUDA® (pembrolizumab) for the treatment of multiple cancer indications

Silicon Valley Bank releases 10th annual Startup Outlook report series based on nearly 1,400 survey responses from technology and healthcare executives in major innovation hubs

Proceeds to advance oral HIF-2α inhibitor, PT2977, into Phase 3 trial in advanced renal cell carcinoma

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the dosing of the first patient in a Phase 1 trial of OTX-TKI (tyrosine kinase inhibitor implant) in patients with wet Age-related Macular Degeneration (AMD).

Reference is made to the stock exchange announcement on 18 February 2019 where Nordic Nanovector ASA (the “Company”) announced that the extraordinary general meeting of the Company had granted the Board of Directors an authorisation to increase the share capital of the Company in connection with a repair offering of up to 777,777 new shares (the “Offer Shares”)

IT Staffing Company Rebrands as Part of Parent Company Structure

Fountainwood will open for business in late summer 2020.

Awarded among the top ten in the Food category for developing an alternative to chemical fertilizer and improving environmental sustainability